News

Facing the treatment challenge of HER2-positive colorectal cancer, we fully understand your urgent desire for more effective and advanced treatment options. Today, we bring major encouraging news from China’s oncology field. **Breakthrough Therapy Is Within Reach: SHR-A1811 Demonstrates Exception...Read more »

Recently, China’s National Medical Products Administration officially approved the combination therapy of Anlotinib Hydrochloride and Penpulimab by Chia Tai Tianqing for the first-line treatment of advanced hepatocellular carcinoma. This marks the tenth approved indication for Anlotinib Hyd...Read more »

Recently, the field of cancer treatment in China has achieved a significant milestone. On January 7, 2025, the National Medical Products Administration officially approved the innovative drug SHR-1701 for market use. It is indicated in combination with chemotherapy as a first-line treatment for l...Read more »

Amidst the ongoing advancements of modern medicine, oncology treatment is evolving towards greater precision, minimal invasiveness, and enhanced patient-centered care. At the Hyperthermia/HIFU Center of Beijing South Region Oncology Hospital, a warm “beam of light” known as “HIF...Read more »

“Doctor, my father is 81 years old. Can he still be treated?” – This brief sentence encapsulates the helplessness, anxiety, and deepest hopes of countless families when facing a serious illness in an elderly loved one. At the Beijing South Region Oncology Hospital International Depart...Read more »

On December 26, 2025, China’s National Medical Products Administration officially included the Boron Neutron Capture Therapy (BNCT) system in the priority review and approval process, marking the beginning of a “golden acceleration period” for this innovative technology in China...Read more »

At the beginning of 2026, China’s oncology treatment field has achieved a major breakthrough. On January 5, the China National Medical Products Administration (NMPA) officially approved the new-generation targeted drug Repotrectinib for the treatment of adult patients with solid tumors harboring ...Read more »

Recently, China’s National Medical Products Administration (NMPA) approved Enhertu for injection for the treatment of specific types of patients with advanced breast cancer, marking a significant advancement in the global fight against breast cancer. This approval is based on the positive r...Read more »

On December 15, 2025, China’s National Medical Products Administration officially approved the market launch of the new anti-cancer drug zurletrectinib (ICP-723). This milestone breakthrough brings unprecedented therapeutic hope to patients worldwide with solid tumors harboring NTRK fusion ...Read more »

On December 24, 2025, China’s National Medical Products Administration (NMPA) approved a significant new tumor treatment technology—the domestically developed Tumor Treating Fields (TTFields) device officially entered the market. This product marks a major breakthrough for China in the field of h...Read more »

Beijing, September 5, 2025 – In the advanced Hyperthermia/HIFU Treatment Center of the Beijing South Region Oncology Hospital International Department, two hopes from different countries and backgrounds were gently illuminated on the same day. **Healing Across Borders: A Heartwarming Story from M...Read more »

  In the Hyperthermia/HIFU (commonly known as “Hyperthermia/HIFU”) room at Beijing South Region Oncology Hospital, a special treatment session had just concluded. Alex (pseudonym), a patient with liver metastasis from abroad, slowly regained consciousness. He instinctively touche...Read more »